Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, Davie, FL, 33328, USA.
Institute for Neuroimmune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL, USA.
Stem Cell Res Ther. 2019 Dec 18;10(1):395. doi: 10.1186/s13287-019-1515-3.
Mesenchymal stromal cells (MSCs), adult stromal cells most commonly isolated from bone marrow (BM), are being increasingly utilized in various therapeutic applications including tissue repair via immunomodulation, which is recognized as one of their most relevant mechanism of action. The promise of MSC-based therapies is somewhat hindered by their apparent modest clinical benefits, highlighting the need for approaches that would increase the efficacy of such therapies. Manipulation of cellular stress-response mechanism(s) such as autophagy, a catabolic stress-response mechanism, with small molecules prior to or during MSC injection could improve MSCs' therapeutic efficacy. Unfortunately, limited information exists on how manipulation of autophagy affects MSCs' response to inflammation and subsequent immunoregulatory properties.
In this study, we exposed BM-MSC precursor cells, "marrow-isolated adult multilineage inducible" (MIAMI) cells, to autophagy modulators tamoxifen (TX) or chloroquine (CQ), together with IFN-γ. Exposed cells then underwent RNA sequencing (RNAseq) to determine the effects of TX or CQ co-treatments on cellular response to IFN-γ at a molecular level. Furthermore, we evaluated their immunoregulatory capacity using activated CD4+ T cells by analyzing T cell activation marker CD25 and the percentage of proliferating T cells after co-culturing the cells with MIAMI cells treated or not with TX or CQ.
RNAseq data indicate that the co-treatments alter both mRNA and protein levels of key genes responsible for MSCs' immune-regulatory properties. Interestingly, TX and CQ also altered some of the microRNAs targeting such key genes. In addition, while IFN-γ treatment alone increased the surface expression of PD-L1 and secretion of IDO, this increase was further enhanced with TX. An improvement in MIAMI cells' ability to decrease the activation and proliferation of T cells was also observed with TX, and to a lesser extent, CQ co-treatments.
Altogether, this work suggests that both TX and CQ have a potential to enhance MIAMI cells' immunoregulatory properties. However, this enhancement is more pronounced with TX co-treatment.
间充质基质细胞(MSCs),最常从骨髓(BM)中分离出来的成体基质细胞,越来越多地被用于各种治疗应用,包括通过免疫调节进行组织修复,这被认为是其最相关的作用机制之一。基于 MSC 的治疗方法的前景受到其明显的适度临床益处的限制,这突出了需要采用能够提高此类治疗方法疗效的方法。在 MSC 注射之前或期间,用小分子操纵细胞应激反应机制(如自噬),一种分解代谢应激反应机制,可以提高 MSC 的治疗效果。不幸的是,关于自噬的操纵如何影响 MSC 对炎症的反应以及随后的免疫调节特性的信息有限。
在这项研究中,我们将骨髓间充质基质细胞前体细胞“骨髓分离的成年多谱系诱导”(MIAMI)细胞暴露于自噬调节剂他莫昔芬(TX)或氯喹(CQ)和 IFN-γ 中。然后,暴露的细胞进行 RNA 测序(RNAseq),以确定 TX 或 CQ 共同处理在分子水平上对细胞对 IFN-γ 的反应的影响。此外,我们通过分析共培养的细胞与未用 TX 或 CQ 处理的 MIAMI 细胞后 CD4+T 细胞激活标志物 CD25 和增殖 T 细胞的百分比,来评估它们的免疫调节能力。
RNAseq 数据表明,共同处理改变了负责 MSC 免疫调节特性的关键基因的 mRNA 和蛋白质水平。有趣的是,TX 和 CQ 也改变了一些针对这些关键基因的 microRNAs。此外,虽然 IFN-γ 单独处理会增加 PD-L1 的表面表达和 IDO 的分泌,但 TX 进一步增强了这种增加。还观察到 TX 处理增强了 MIAMI 细胞降低 T 细胞激活和增殖的能力,CQ 处理也有一定程度的增强。
总的来说,这项工作表明 TX 和 CQ 都有可能增强 MIAMI 细胞的免疫调节特性。然而,与 CQ 处理相比,这种增强更为明显。